Pyruvate Dehydrogenase E1-alpha subunit antibody | knockout validation | Abcam ab110334

This is a knockout-validated antibody summary, based on the publication "PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Pyruvate Dehydrogenase E1-alpha subunit antibody | knockout validation | Abcam ab110334 figure 1
Figure 1. Western blotting results, where the PDHA1 protein expression in the parental LNCaP cells is strongly positive, but its expression in the PDHA1 KO cells is almost negative with two different PDHA1 antibodies. GAPDH was used as a loading control. From [1].
Antibody information

Mouse monoclonal IgG1

Company: Abcam

Antibody: Pyruvate Dehydrogenase E1-alpha subunit

Catalog number: ab110334

Summary: Mouse monoclonal IgG1 kappa against full-length native protein (purified) corresponding to human Pyruvate Dehydrogenase E1-alpha subunit. Reacts with mouse, rat, cow, human, C. elegans, Drosophila, and zebrafish. Suitable for western blot, immunocytochemistry/immunofluorescence, immunohistochemistry (frozen), and flow cytometry.

Validation Method

Western blot

Sample

Control and PDHA1-KO LNCaP cell lines. Cells were lysed in RIPA buffer containing a cocktail of protease inhibitors.

Blocking agent

5% milk (Bio-Rad, Hercules, CA).

Secondary incubation

Horseradish peroxidase-conjugated (HRP) antibodies.

Detection

Enhanced chemiluminescence assay reagents (GE Healthcare) and X-ray films.

Clone note

The same clone (8D10E6) is sold as Abcam ab110334; Invitrogen 45-6600.

References
  1. Li Y, Li X, Li X, Zhong Y, Ji Y, Yu D, et al. PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. Oncotarget. 2016;7:53837-53852 pubmed publisher